Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.

@article{Scher1988NeoadjuvantM,
  title={Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.},
  author={Howard I. Scher and Alexandre Yagoda and Harry W. Herr and Cora N Sternberg and G. L. Bosl and Michael J. Morse and Pramod G. Sogani and Robin Caird Watson and D. David Dershaw and Victor Reuter},
  journal={The Journal of urology},
  year={1988},
  volume={139 3},
  pages={
          470-4
        }
}
Of 50 patients with bladder cancer given 1 to 5 cycles of neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin in a pilot phase I and II study 63 per cent of 41 with pure transitional cell stage T2-4 lesions responded. While significant downstaging occurred by transurethral resection of the bladder in 70 per cent and by cytology in 60 per cent of the patients, the final T response rate by all noninvasive clinical staging procedures, including sonography and computerized tomography… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS